Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Serotonin-dopamine interaction in the induction and maintenance of L-DOPA-induced dyskinesias

Carta, Manolo LU ; Carlsson, Thomas LU ; Muñoz, Ana LU ; Kirik, Deniz LU and Björklund, Anders LU orcid (2008) In Progress in Brain Research 172. p.465-478
Abstract

Appearance of dyskinesia is a common problem of long-term Levodopa (L-DOPA) treatment in Parkinson's disease (PD) patients and represents a major limitation for the pharmacological management of the motor symptoms in the advanced stages of disease. An increasing body of evidence points to dopamine released as a false neurotransmitter from the striatal serotonin terminals as the main pre-synaptic determinant of L-DOPA-induced dyskinesia. Here we review the animal experimental and human clinical data in support of this view, which point to the serotonin system as a promising target for anti-dyskinetic therapy in PD patients under L-DOPA medication.

Please use this url to cite or link to this publication:
author
; ; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Animals, Clinical Trials as Topic, Dopamine, Dyskinesia, Drug-Induced, Humans, Levodopa, Parkinson Disease, Parkinsonian Disorders, Presynaptic Terminals, Protein Isoforms, Receptors, Dopamine, Receptors, Serotonin, Serotonin, Journal Article, Research Support, Non-U.S. Gov't, Review
in
Progress in Brain Research
volume
172
pages
14 pages
publisher
Elsevier
external identifiers
  • wos:000280603200023
  • pmid:18772046
  • scopus:50349084288
  • pmid:18772046
ISSN
1875-7855
DOI
10.1016/S0079-6123(08)00922-9
language
English
LU publication?
yes
id
0304601e-3652-43d5-ab6e-6c40e534c4ed (old id 1243349)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/18772046?dopt=Abstract
date added to LUP
2016-04-04 09:22:58
date last changed
2022-02-21 00:32:04
@article{0304601e-3652-43d5-ab6e-6c40e534c4ed,
  abstract     = {{<p>Appearance of dyskinesia is a common problem of long-term Levodopa (L-DOPA) treatment in Parkinson's disease (PD) patients and represents a major limitation for the pharmacological management of the motor symptoms in the advanced stages of disease. An increasing body of evidence points to dopamine released as a false neurotransmitter from the striatal serotonin terminals as the main pre-synaptic determinant of L-DOPA-induced dyskinesia. Here we review the animal experimental and human clinical data in support of this view, which point to the serotonin system as a promising target for anti-dyskinetic therapy in PD patients under L-DOPA medication.</p>}},
  author       = {{Carta, Manolo and Carlsson, Thomas and Muñoz, Ana and Kirik, Deniz and Björklund, Anders}},
  issn         = {{1875-7855}},
  keywords     = {{Animals; Clinical Trials as Topic; Dopamine; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Parkinsonian Disorders; Presynaptic Terminals; Protein Isoforms; Receptors, Dopamine; Receptors, Serotonin; Serotonin; Journal Article; Research Support, Non-U.S. Gov't; Review}},
  language     = {{eng}},
  pages        = {{465--478}},
  publisher    = {{Elsevier}},
  series       = {{Progress in Brain Research}},
  title        = {{Serotonin-dopamine interaction in the induction and maintenance of L-DOPA-induced dyskinesias}},
  url          = {{http://dx.doi.org/10.1016/S0079-6123(08)00922-9}},
  doi          = {{10.1016/S0079-6123(08)00922-9}},
  volume       = {{172}},
  year         = {{2008}},
}